Compare CABO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABO | PRTA |
|---|---|---|
| Founded | 1980 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.5M | 449.7M |
| IPO Year | 2015 | 2013 |
| Metric | CABO | PRTA |
|---|---|---|
| Price | $26.68 | $8.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $125.67 | $19.00 |
| AVG Volume (30 Days) | 191.6K | ★ 471.8K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $1,501,423,000.00 | $814,000.00 |
| Revenue This Year | N/A | $1,111.38 |
| Revenue Next Year | $6.83 | N/A |
| P/E Ratio | ★ N/A | $35.73 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $25.26 | $7.73 |
| 52 Week High | $180.74 | $11.80 |
| Indicator | CABO | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 33.11 | 51.70 |
| Support Level | N/A | $8.91 |
| Resistance Level | $45.01 | $9.36 |
| Average True Range (ATR) | 3.23 | 0.41 |
| MACD | -1.18 | 0.05 |
| Stochastic Oscillator | 10.85 | 70.19 |
Cable One Inc is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. The company derives majority of its revenue from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.